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Background: Serum levels of perfluorooctanoic acid (PFOA) have been associated with decreased 
renal function in cross-sectional analyses, but the direction of the association is unclear.
oBjectives: We examined the association of measured and model-predicted serum PFOA concen-
trations with estimated glomerular filtration rate (eGFR), a marker of kidney function, in a highly 
exposed population (median serum PFOA, 28.3 ng/mL).
Methods: We measured serum creatinine, PFOA, perfluorooctane sulfonate (PFOS), per-
fluorononanoic acid (PFNA), and perfluorohexane sulfonate (PFHxS) and calculated eGFR in 
9,660 children 1 to < 18 years of age at study enrollment. We predicted concurrent and histori-
cal serum PFOA concentrations using a validated environmental, exposure, and pharmacokinetic 
model based on individual residential histories, and used linear regression to estimate the association 
between eGFR and measured and predicted serum PFOA concentrations. We hypothesized that 
predicted serum PFOA levels would be less susceptible to reverse causation than measured levels.
results: An interquartile range increase in measured serum PFOA concentrations [IQR 
ln(PFOA) = 1.63] was associated with a decrease in eGFR of 0.75 mL/min/1.73 m2 (95% CI: 
–1.41, –0.10; p = 0.02). Measured serum levels of PFOS, PFNA, and PFHxS were also cross-
sectionally associated with decreased eGFR. In contrast, predicted serum PFOA concentrations 
at the time of enrollment were not associated with eGFR (–0.10; 95% CI: –0.80, 0.60; p = 0.78). 
Additionally, predicted serum PFOA levels at birth and during the first ten years of life were not 
related to eGFR.
conclusions: Our findings suggest that the cross-sectional association between eGFR and serum 
PFOA observed in this and prior studies may be a consequence of, rather than a cause of, decreased 
kidney function.
key words: adolescent, children, eGFR, kidney function, perfluoroalkyl acids, perfluoro octane 
sulfonate, perfluorooctanoic acid, reverse causation. Environ Health Perspect 121:625–630 
(2013). http://dx.doi.org/10.1289/ehp.1205838 [Online 11 March 2013]
Chronic kidney disease affects approximately 
13% of the U.S. population, and its preva­
lence has been increasing over the past 20 years 
(Coresh et al. 2007). Chronic kidney disease is 
an important health problem that frequently 
leads to kidney failure, and is an important risk 
factor for cardiovascular disease (Sarnak et al. 
2003; Wright and Hutchison 2009).
Perfluoroalkyl acids (PFAAs) are a class 
of synthetic chemicals that have been used 
in a wide range of commercial and indus­
trial applications since the 1950s. Uses 
include stain resistant sprays for carpeting 
and upholstery, food contact paper coat­
ings, nonstick cooking surfaces, and water­
proofing sprays. Many PFAAs are persistent 
environmental pollutants (Lau et al. 2007), 
and > 95% of Americans participating in the 
2007–2008 National Health and Nutrition 
Examination Survey (NHANES) had detect­
able concentrations of the four most common 
PFAAs—perfluorooctanoic acid (PFOA), 
perfluorooctane sulfonate (PFOS), perfluoro­
nonanoic acid (PFNA), and perfluorohexane 
sulfonate (PFHxS)—in their blood (Kato et al. 
2011). Mean serum concentrations of PFOS 
and PFOA have decreased in recent years in 
the United States (Bartell et al. 2010; Kato 
et al. 2011; Olsen et al. 2012), possibly due to 
the cessation of production of PFOS by large 
U.S. producers and efforts to decrease release 
of PFOA into the environment. On the other 
hand, serum concentrations of PFNA have 
been increasing over the past 10–15 years 
(Kato et al. 2011).
Epidemiological studies suggest that expo­
sure to PFOA and PFOS may be associated 
with several risk factors for kidney disease, 
including increased total and low­density 
lipoprotein (LDL) cholesterol (Costa et al. 
2009; Frisbee et al. 2010; Nelson et al. 2010; 
Steenland et al. 2009b), increased levels of 
uric acid (Costa et al. 2009; Shankar et al. 
2011a; Steenland et al. 2010b), increased 
prevalence of insulin resistance and metabolic 
syndrome (Lin et al. 2009), and increased risk 
of diabetes (Leonard et al. 2008; Lundin et al. 
2009), although results have not been entirely 
consistent (MacNeil et al. 200; Steenland 
et al. 2010a). Although previous studies of 
populations that were occupationally or oth­
erwise highly exposed to PFOA did not find 
an association between serum PFOA concen­
trations and blood urea nitrogen or serum 
creatinine (Costa et al. 2009; Emmett et al. 
2006), a recent analysis of NHANES data 
found that serum concentrations of PFOA 
and PFOS were associated with decreased esti­
mated glomerular filtration rate (eGFR) and 
increased odds of having an eGFR < 60 mL/
min/1.73 m2, a clinically relevant cut point 
indicative of chronic kidney disease in adults 
(Shankar et al. 2011b).
Because NHANES is a cross­sectional 
survey, Shankar et al. (2011b) were unable 
to determine whether high levels of PFOA 
and PFOS in serum preceded reduced kid­
ney function and chronic kidney disease, 
or vice versa. In addition, serum concentra­
tions of PFOA and PFOS are moderately or 
strongly correlated in the general population 
(Calafat et al. 2007), making it difficult to 
distinguish the association with one from the 
other. Finally, the association between PFAA 
exposure and kidney function among chil­
dren or adolescents has never been examined. 
Because chronic kidney disease in children 
may eventually require dialysis or kidney trans­
plantation, and early diagnosis is a key com­
ponent of successful treatment, understanding 
environmental risk factors is important.
Accordingly, the objective of this study 
was to evaluate the cross­sectional and lon­
gitudinal association between measures of 
PFAA exposure and kidney function among 
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children and adolescents who were highly 
exposed to PFOA from contaminated water 
supplies, but exposed to typical U.S. levels 
of PFOS, PFNA, and PFHxS. We evaluated 
these associations within the context of the 
data gathered in the C8 Health Project, a 
large, population­based health survey of resi­
dents living in the mid­Ohio River Valley and 
exposed to high levels of PFOA in drinking 
water resulting from contamination from a 
local industrial facility (Frisbee et al. 2009).
Materials and Methods
Population and study design. The C8 Health 
Project resulted from the settlement of a class­
action lawsuit filed in 2002 by residents living 
near the DuPont Washington Works plant in 
West Virginia after PFOA released from the 
plant contaminated drinking­water supplies 
along the mid­Ohio River Valley, as previ­
ously described (Frisbee et al. 2009). Residents 
were eligible to participate in the C8 Health 
Project if they could document consumption 
of public drinking water from contaminated 
water districts or a small number of private 
wells known to be contaminated for at least 
1 year between 1950 and 3 December 2004 
at their primary residence, workplace, or 
school. Participants were enrolled in the C8 
Health Project between 1 August 2005 and 
31 August 2006, and all participants provided 
written informed consent before enrollment. 
An estimated 80% of then­residents of eli­
gible water districts enrolled in the C8 Health 
Project. The C8 Health Project was approved 
by the respective institutional review boards 
(IRBs) associated with the principal investiga­
tors of that study (Frisbee et al. 2009). The 
specific analysis reported here was approved 
by the Brown University IRB.
On enrollment in the C8 Health Project, 
participants completed self­administered ques­
tionnaires on demographics, personal health 
history, residential history, and lifestyle habits 
(Brookmar Inc. 2005) and provided a venous 
blood sample. Information collected included 
sex, race (non­Hispanic white vs. other), 
height, weight, household income (≤ $30,000 
vs. > $30,000), education (< 12 years, high 
school diploma or GED, some college, bach­
elor degree or higher), smoking status (ever 
vs. never) and regular exercise (yes vs. no). 
The complete questionnaire is available online 
Brookmar Inc. 2005).
Blood sampling and laboratory  methods. 
Blood samples were centrifuged, divided 
into aliquots, and refrigerated until ship­
ment to the laboratory for analysis. Fasting 
before blood sampling was not required. 
Serum creatinine was measured at an accred­
ited clinical diagnostic laboratory (LabCorp, 
Inc., Burlington, NC) using the Jaffe reac­
tion method. Laboratory analysis of PFAAs 
(Exygen Research Inc., State College, PA) 
has been previously described (Frisbee 
et al. 2009).
Estimated historical PFOA exposure. A 
unique feature of this population is that PFOA 
exposures were attributable predominantly to 
documented and well­defined pollutant releases 
from a specific industrial plant. Local PFOA 
releases to both air and surface water began in 
the early 1950s, increased until the late 1990s, 
and declined rapidly thereafter. Consequently, 
we used a series of linked environmental, 
exposure, and pharmacokinetic models in 
conjunction with self­reported residential his­
tories to estimate historical PFOA exposures 
for all participants in the C8 Health Project, 
as previously described (Shin et al. 2011a). 
Briefly, estimated yearly PFOA releases from 
the plant were used along with meteorological 
and hydrogeological information to estimate 
concentrations of PFOA in air and water over 
time. Using residential histories linked to pub­
lic water systems through a geographic infor­
mation system, standard assumptions about air 
and water intake rates and body weight, and a 
PFOA half­life of 3.5 years (Olsen et al. 2007), 
yearly PFOA serum concentrations were esti­
mated for each participant.
Measured serum PFOA concentrations 
from blood sampled at time of enrollment 
in the C8 Health Project (2005–2006) are 
not necessarily strongly correlated with his­
torical modeled PFOA serum concentra­
tions from several years to decades earlier 
because of changing concentrations in drink­
ing water, varying water intake over time, 
residential mobility, and a serum half­life of 
about 2–4 years (Bartell et al. 2010; Olsen 
et al. 2007). However, the Spearman rank 
correlation coefficient (rS) between mea­
sured and modeled serum PFOA concentra­
tions in 2005–2006 (at the time of the C8 
Health Project survey) was 0.67 overall, and 
higher for participants who resided or worked 
in the contaminated area for at least 5 years 
before sample collection and provided daily 
public well water consumption information 
(rS = 0.82) (Shin et al. 2011a, 2011b). In the 
current analysis, we used model­based esti­
mates without any adjustment for measured 
serum PFOA concentrations (i.e., uncali­
brated estimates). Because participants were 
not exposed to PFAAs other than PFOA via 
contaminated drinking water, we could not 
reliably model historical exposures to PFOS, 
PFNA, or PFHxS, and we could examine only 
associations between measured serum concen­
trations of these compounds and kidney func­
tion in cross­sectional analyses.
We restricted the current study to 9,783 
study participants ≥ 1 to < 18 years of age 
at enrollment, with data available on serum 
creatinine and height to calculate eGFR, and 
measured serum PFOA concentrations. We 
calculated body mass index (BMI) z­score 
based on the 2000 Centers for Disease 
Control and Prevention (CDC) growth charts 
of BMI for age and sex (CDC 2009) using 
SAS (version 9.2; SAS Institute Inc., Cary, 
NC). We calculated eGFR using the follow­
ing formula (Schwartz and Work 2009):
 eGFR = k × height in cm/serum creatinine, 
 [1]
where k is an age­specific constant equal to 
0.7 for males 13–18 years of age and 0.55 
otherwise. After excluding 123 subjects with 
implausible values of BMI z­score, data on 
9,660 participants were available for analyses.
In a subsample of 6,060 participants who 
consented to research use of their residential 
address history, we estimated serum PFOA 
concentrations at the time of enrollment. 
Additionally, we estimated historical serum 
PFOA concentrations at specific time points 
that potentially represent critical windows of 
exposure, including a) birth, b) birth through 
10 years of age (or current age if < 10 years 
old), and c) during the 3 years before enroll­
ment. Cumulative measures of exposure were 
calculated by summing estimated yearly serum 
PFOA concentrations over the specified time 
period. Serum concentrations at birth and 
during the first 10 years of life could only 
be estimated reliably for participants born 
after 1989 (n = 4,787), because contaminant 
releases during this time period were the 
dominant source of exposure, providing the 
most reliable exposure estimates.
For a subsample of participants with esti­
mated PFOA exposure at birth whose moth­
ers also participated in the C8 Health Project 
(n = 3,527), we were able to match children 
to their mothers and obtain information 
on maternal smoking, maternal education, 
maternal exercise, and maternal BMI, as pre­
viously described (Mondal et al. 2012).
Statistical analyses. Household income was 
missing in 21%, BMI in 0.8%, and smok­
ing in 0.1% of participants. We used multiple 
imputation to address missing covariate data. 
All available covariates were used to impute 
missing values. Twenty imputations were gen­
erated to obtain accurate information on the 
variability in the imputed values (Graham et al. 
2007). Markov chain Monte Carlo imputa­
tion was used with 200 burn­in iterations and 
100 iterations between each imputation. The 
parameter estimates and standard errors deter­
mined from each imputed data set were pooled 
into a final parameter estimate and variance 
using the method of Rubin (1987).
We used linear regression to evalu­
ate the cross­sectional association between 
measured serum concentrations of PFOA, 
PFOS, PFNA, and PFHxS and eGFR among 
all 9,660 participants. Serum PFAA concen­
trations were log­transformed, modeled as 
PFAA exposure and eGFR in children and adolescents
Environmental Health Perspectives • volume 121 | number 5 | May 2013 627
linear continuous variables, and entered into 
separate regression models. We performed 
additional analyses considering quartiles of 
serum PFAA concentrations. Tests for lin­
ear trend were performed by assigning the 
median PFAA concentration in each quartile 
to all participants in that quartile and includ­
ing the term as a continuous variable in a 
linear regression model. In initial models we 
controlled for age (natural cubic spline with 
3 degrees of freedom), sex, race, smoking, and 
household income. In sensitivity analyses we 
additionally controlled for regular exercise 
and BMI z­score (natural cubic spline with 
3 degrees of freedom). As a further sensitiv­
ity analysis, we additionally adjusted for total 
cholesterol, which could represent either a 
potential confounder or a causal intermediate.
We used an analogous modeling strat­
egy to evaluate the association of predicted 
serum PFOA concentrations at enrollment 
in the C8 Health Project, at birth, from birth 
to 10 years of age (early life), and over the 
3 years before enrollment (recent) with eGFR 
calculated based on serum creatinine mea­
sured at enrollment in the C8 Health Project. 
When considering predicted serum PFOA 
levels at birth we did not control for chil­
dren’s smoking because none of the partici­
pants would have been smokers at birth. In 
sensitivity analyses, in the subset of children 
whose mothers also participated in the C8 
Health Project, we assessed the association 
of predicted serum PFOA concentrations at 
birth with eGFR additionally controlling for 
maternal age (spline with 3 degrees of free­
dom), maternal smoking, maternal education, 
maternal BMI (spline with 3 degrees of free­
dom), and maternal regular exercise.
All analyses were conducted using SAS 
software (version 9.2) and R 2.12.1 (R Project 
for Statistical Computing, Vienna, Austria). A 
two­sided p­value of < 0.05 was considered 
statistically significant.
Results
Characteristics of the 9,660 participants ≥ 1 to 
< 18 years of age on enrollment and with mea­
surements available on serum PFAAs, serum 
creatinine, and height are shown in Table 1. 
These participants did not differ materially 
from all participants in the C8 Health Project 
population in this age range [see Supplemental 
Material, Table S1 (http://dx.doi.org/10.1289/
ehp.1205838)]. Participants with measured 
serum PFOA in the highest quartile tended to 
be younger and were more likely to be male 
and never smokers and to have a higher house­
hold income and lower BMI z­score compared 
with other participants. Among participants 
included in these analyses, the median concen­
tration of PFOA in serum was 28.3 ng/mL, 
with a range of 0.7–2,071 ng/mL. As expected, 
median concentrations of serum PFOS, PFNA, 
and PFHxS were lower than those of PFOA 
at 20.0, 1.5, and 5.2 ng/mL, respectively. 
Measured serum concentrations of PFOA were 
only weakly correlated with PFOS, PFNA, or 
PFHxS in serum (rS = 0.10–0.26), whereas 
correlations between serum concentrations 
of PFOS, PFNA, and PFHxS were stronger 
(rS = 0.24–0.54) (see Supplemental Material, 
Table S2), as expected, because the predomi­
nant source of exposure to PFOA was differ­
ent from that of other PFAAs. Mean eGFR 
(Table 1) was well within the normal ranges for 
children and adolescents (Hogg et al. 2003), 
with 0.3% of participants (n = 29) with an 
eGFR below normal for their age and sex.
Measured serum PFAA concentra-
tions and eGFR. A shift from the 25th per­
centile to the 75th percentile of measured, 
natural log–transformed concentrations of 
PFOA in serum [interquartile range (IQR) 
ln(PFOA) = 1.63] was associated with a 
decrease in eGFR of 0.75 mL/min/1.73 m2 
(95% CI: –1.41, –0.10; p = 0.02) adjusting 
for age, sex, race, smoking status, and house­
hold income (Table 2). Further adjustment 
for regular exercise and BMI z­score did not 
materially alter the results, nor did further 
adjustment for total cholesterol. Measured 
concentrations of PFOS, PFNA, or PFHxS in 
serum were also significantly associated with 
lower eGFR.
Considering quartiles of measured serum 
PFAA concentrations, eGFR decreased mono­
tonically with increasing PFOA, PFOS, and 
PFHxS levels, adjusting for age, sex, race, 
smoking status, and household income 
(Figure 1). This association was strongest with 
serum concentrations of PFOS, with a decrease 
in eGFR of 2.3, 2.6, and 2.9 mL/min/1.73 m2 
for the second, third, and fourth quartile of 
serum PFOS, respectively, compared with 
the lowest quartile. There was a statistically 
significant linear trend between eGFR and 
PFOS (ptrend across quartiles = 0.0001), PFNA 
(ptrend = 0.005), and PFHxS (ptrend = 0.004), 
but not PFOA (ptrend = 0.30).
Estimated serum PFOA concentrations 
and eGFR. Predicted serum PFOA concen­
trations at the time of enrollment were not 
associated with eGFR, nor were predicted 
historical serum PFOA concentrations dur­
ing the first 10 years or life, and in the 3 years 
before enrollment (Table 2). Additionally, 
predicted historical serum PFOA concentra­
tions at the time of birth were not associated 
with eGFR (Table 3). Additional control for 
maternal factors did not materially alter the 
association between predicted serum PFOA 
concentrations at birth and eGFR. Model­
predicted serum PFOA concentrations at 
the time of enrollment, in the 3 years before 
enrollment (recent exposure), during the first 
Table 1. Characteristics of 9,660 study participants < 18 years of age at enrollment into the C8 Health 
Project.
Characteristic Overall
Quartiles of serum PFOA concentrations
1 2 3 4
Measured serum PFOA [ng/mL (range)] 0.7–2071 0.7–< 12.8 12.8–< 28.3 28.3–< 65.4 ≥ 65.4–2,071
Measured serum PFOA [ng/mL (median)] 28.3 9.1 18.6 41.3 139.2
Age [years (mean ± SD)] 12.4 ± 3.8 12.8 ± 3.7 12.6 ± 3.8 12.4 ± 3.8 12.0 ± 3.8
Female [n (%)] 4,684 (48) 1,303 (54) 1,203 (49) 1,144 (47) 1,034 (43)
White [n (%)] 9,346 (97) 2,326 (97) 2,347 (97) 2,349 (97) 2,324 (96)
Ever smoker [n (%)] 92 (1.0) 30 (1.3) 37 (1.5) 18 (0.7) 7 (0.3)
Regular exercise [n (%)] 3,939 (41) 889 (37) 922 (38) 1,068 (44) 1,060 (44)
Household income ≤ $30,000/year [n (%)] 3,679 (48) 1,249 (52) 1,217 (50) 1,089 (45) 1,007 (42)
BMI z-score (mean ± SE) 0.6 ± 1.2 0.63 ± 0.02 0.58 ± 0.03 0.56 ± 0.03 0.51 ± 0.03
eGFR [mL/min/1.73 m2 (mean ± SD)] 133.0 ± 23.9 133.0 ± 24.1 132.6 ± 22.6 133.1 ± 26 133.2 ± 22.9
Table 2. Associations between serum perfluoroalkyl acid (PFAA) concentrations and estimated glomerular 
filtration rate (eGFR).a
PFAA n IQR
Model 1b Model 2c
Change in eGFR  
(95% CI)c p-Value
Change in eGFR  
(95% CI)c p-Value
Measured
PFOA 9,660 1.63 –0.75 (–1.41, –0.10) 0.02 –0.73 (–1.38, –0.08) 0.03
PFOS 9,660 0.64 –1.10 (–1.66, –0.53) 0.0001 –1.34 (–1.91, –0.77) < 0.0001
PFNA 9,660 0.51 –0.83 (–1.35, –0.30) 0.002 –0.88 (–1.41, –0.36) 0.001
PFHxS 9,660 1.27 –0.95 (–1.57, –0.32) 0.003 –1.02 (–1.64, –0.40) 0.001
Estimated PFOA
Earlyd 4,787 2.10 –0.03 (–0.99, 0.93) 0.95 –0.09 (–1.04, 0.87) 0.86
Recente 6,060 1.88 –0.04 (–0.76, 0.68) 0.91 –0.06 (–0.77, 0.65) 0.87
Enrollmentf 6,060 1.84 –0.10 (–0.80, 0.60) 0.78 –0.12 (–0.81, 0.58) 0.75
aExpressed as the mean change in eGFR per interquartile range (IQR) increase in each natural log-transformed PFAA.
bModel 1: adjusted for age, sex, race, smoking, and household income. cModel 2: adjusted for model 1 covariates plus 
regular exercise and BMI z-score. dFirst 10 years of life, or current age if < 10 years of age. eDuring 3 years before enroll-
ment. fAt time of enrollment (2005–2006).
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10 years of life (early exposure), and at birth 
were moderately to strongly correlated with 
one another (Table 4). 
Discussion
In this large, community­based study, partici­
pants had a wide range of exposures to PFOA 
via contaminated drinking water, but back­
ground exposure to the three other common 
PFAAs that we measured, resulting in weak 
correlations of PFOA with PFOS, PFNA, 
and PFHxS (rS = 0.10–0.26). This allowed 
us to evaluate the association between serum 
PFOA and kidney function with minimal 
concerns of potential confounding by co­
exposure to other PFAAs. We also had the 
unique opportunity to evaluate associations 
between estimates of historical serum PFOA 
levels and kidney function using a detailed 
exposure model previously developed in this 
population (Shin et al. 2011a). We found 
that measured serum PFOA levels were asso­
ciated with decreased eGFR, but this associa­
tion was not found when we used predicted 
serum PFOA concentrations as a measure 
of exposure.
The results of our cross­sectional analy­
ses based on measured serum PFOA levels are 
generally consistent with a study by Shankar 
et al. (2011b) of adult NHANES partici­
pants from 1999–2008, which reported cross­
sectional associations between serum PFOA 
and PFOS levels and decreased eGFR, as well 
as increased odds of chronic kidney disease 
(defined as eGFR < 60 mL/min/1.73 m2). 
Although NHANES participants had much 
lower median serum PFOA levels (4.1 ng/mL) 
compared with our highly exposed popula­
tion (28.3 ng/mL), the magnitude of the asso­
ciation estimated for the NHANES population 
was larger (–5.7 mL/min/1.73 m2; 95% CI: 
–7.9, –3.5 between the first and fourth quartile 
of serum PFOA compared with –0.80 mL/
min/1.73 m2; 95% CI: –2.12, 0.52 observed 
in the present analysis). This may be explained, 
at least in part, by the difference in the mag­
nitude of exposure between the two study 
populations. For example, those in the 75th 
percentile of serum PFOA in the NHANES 
population would be included in the lowest 
quartile of our population. Although the dose–
response relationship between serum PFOA 
and eGFR appeared to be approximately 
linear at the lower serum PFOA concentra­
tions reported among NHANES participants 
(Shankar et al. 2011b), our results suggest that, 
if in fact increased serum PFOA levels cause 
decreased kidney function, the dose–response 
curve may flatten at higher PFOA concen­
trations (e.g., saturation). The difference in 
ages between the two populations could also 
explain differences in the reported associations. 
GFR changes throughout childhood and ado­
lescence, the developmental periods studied 
here (1 to < 18 years), whereas Shankar et al. 
(2011b) studied adults ≥ 20 years of age.
Even in the absence of confounding or 
other sources of bias, it would not be pos­
sible to determine whether serum PFAA lev­
els cause, or are a result of, decreased kidney 
function, or some combination of the two, 
based on a cross­sectional study. The causal 
directed acyclic graph shown in Figure 2 
illustrates the potential for reverse causation 
(Hernan and Cole 2009). We are interested in 
estimating the causal effect of the biologically 
effective dose of PFOA on kidney function, 
which we approximate by relating serum  levels 
of PFOA (an imperfect marker of the bio­
logically effective dose) to eGFR (an imper­
fect marker of kidney function), controlling 
for common causes of PFOA exposure and 
kidney disease that may confound the asso­
ciation. Reverse causation occurs when kid­
ney function (the outcome) alters our  chosen 
marker of  exposure (serum PFOA).
Decreased GFR could plausibly lead to 
increased serum concentrations of PFAAs. 
Pharmacokinetic studies in animals have 
demonstrated that PFOA and PFOS are 
distributed primarily in serum, kidney, and 
liver (Lau et al. 2007) and are excreted by the 
kidneys without undergoing biotransforma­
tion (Han et al. 2012). In humans, PFOA is 
secreted from the blood into urine through 
the apical membrane of the proximal tubule 
cells and reabsorbed back into the blood 
through the basolateral membrane via uptake 
and efflux transport proteins (Han et al. 
2012). However, because a small fraction of 
PFAAs are not reabsorbed in the kidney (Han 
et al. 2012), a decreased rate of filtration 
through the glomerulus (i.e., decreased GFR) 
could potentially result in slower elimination 
and a consequent increase in serum PFAAs 
over time. In addition, decreased GFR could 
Figure 1. Mean change in eGFR by quartiles (Q) of measured PFAA concentrations in serum (mL/min/1.73 m2) 
adjusted for age, sex, race, smoking status, and household income. Error bars represent 95% CIs; p-values 
for trend = 0.30 for PFOA, 0.0001 for PFOS, 0.005 for PFNA, and 0.004 for PFHxS.
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Table 4. Spearman correlation coefficients among measured and historical estimates of serum PFOA 
concentrations.
Serum PFOA
Measured at 
enrollment
Predicted at 
enrollment
Predicted 
at birth
Predicted 
early life
Predicted 
recent
Measured at enrollment 1.00
Predicted at enrollment 0.73a 1.00
Predicted at birth 0.43b 0.53b 1.00
Predicted early life 0.66b 0.87b 0.68b 1.00
Predicted recent 0.73a 0.997a 0.53b 0.88b 1.00
aAmong 6,060 subjects. bAmong 4,787 subjects born in 1990 or later.
Table 3. Associations between estimated serum PFOA concentrations at birth and eGFR.a
Covariates IQR n Change in eGFR (95% CI) p-Value
PFOA at birth
Model 1b 1.83 4,787 –0.11 (–0.96, 0.74) 0.80
Model 2c 1.83 3,527 –0.05 (–1.02, 0.91) 0.91
Model 3d 1.83 3,527 –0.01 (–0.96, 0.98) 0.99
aExpressed as the mean change in eGFR per interquartile range (IQR) increase in estimated, natural log-transformed, 
serum PFOA concentrations at birth. bModel 1: adjusted for age, sex, race, and household income. cModel 2: adjusted 
for model 1 covariates plus maternal age, maternal smoking, and maternal education. dModel 3: adjusted for model 2 
covariates plus maternal exercise and maternal BMI.
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also decrease the rate of travel through the 
renal tubules, potentially increasing the time 
available for PFAA reabsorption and poten­
tially increasing concentrations of PFAAs in 
serum. Finally, people with decreased kidney 
function may sometimes experience increased 
thirst (National Kidney Foundation 2008), 
which in this population, if associated with 
increased intake of contaminated water, could 
also lead to increased PFOA in serum.
On the other hand, animal studies suggest 
that the kidney could be a target organ for 
effects of PFAA exposure. Toxicological stud­
ies have found changes in kidney histology 
and organ weights among rodents exposed 
to PFOA (Cui et al. 2009; Kennedy et al. 
2004). In vitro studies using several cell types 
have found that PFAA exposure increases the 
permeability and fluidity of cell membranes 
(Hu et al. 2003; Qian et al. 2010), which are 
similar to changes seen in acute kidney injury 
in rats (Sutton 2009).
To evaluate the question of whether 
PFOA in serum causes decreased kidney func­
tion or vice versa, we evaluated the association 
between predicted serum PFOA concentra­
tions and eGFR measured upon enrollment. 
As illustrated in Figure 2B, biologic expo­
sure is determined by environmental levels 
of PFOA, which can also be used to predict 
serum levels of PFOA. Because reduced kid­
ney function cannot affect predicted serum 
PFOA concentrations, analyses using the 
predicted levels as the exposure measure are 
not susceptible to the problem of reverse cau­
sation. Specifically, because subject­specific 
measures of water intake or renal clearance 
were not used in our prediction models, these 
factors cannot influence predicted serum 
PFOA concentrations.
We observed an association between 
measured, but not predicted, serum PFOA. 
One possible explanation for these results is 
that reduced kidney function leads to higher 
measured serum levels of PFOA. Under this 
scenario, our results could be equivalently 
interpreted as showing that a 1­unit increase 
in eGFR is associated with a 2.17­unit 
decrease in measured ln(PFOA) in serum 
among the population studied here, adjusting 
for all the same potential confounders.
Our finding that PFOA was less strongly 
associated with kidney function than other 
PFAAs [Figure 1; see also Supplemental 
Material, Table S3 (http://dx.doi.org/10.1289/
ehp.1205838)] supports this reverse causality 
hypothesis. To see this, recall that in this popu­
lation there was large variability in individual 
PFOA exposures (driven primarily by con­
taminant levels in the local water supply) but 
much less variation in individual exposures to 
other PFAAs. In this setting, and assuming that 
kidney function does indeed influence serum 
levels of all PFAAs, then one would expect 
small variations in kidney function to have 
less of an impact on measured serum PFOA 
levels than on measured serum levels of other 
PFAAs. Thus, if kidney function does influence 
serum levels of PFAAs, in this population we 
would expect to find that PFOA would be less 
strongly associated with kidney function than 
other PFAAs—exactly the pattern of results 
observed in this study.
Similarly, reverse causation could poten­
tially also explain the difference in the magni­
tude of association between kidney function 
and PFOA reported by Shankar et al. (2011b) 
and the cross­sectional association reported 
here. For example, if the association observed 
by Shankar et al. (2011b) in the general pop­
ulation was attributable solely to metabolic 
differences (reverse causation), one would 
expect that association to be attenuated in 
our population, where environmental expo­
sure to PFOA varied widely across individuals 
 residing in different water districts.
An alternative explanation for our observa­
tion that kidney function was associated with 
measured, but not predicted, serum PFOA 
is that our predictions of historical PFOA 
serum levels might be highly misclassified. 
Although we cannot directly address this pos­
sibility, we note that predicted PFOA serum 
concentrations at the time of enrollment were 
strongly correlated with measured levels of 
serum PFOA (rS = 0.73). Additionally, pre­
dicted historical levels of serum PFOA have 
been associated with other health outcomes in 
this population (Lopez­Espinosa et al. 2011; 
Savitz et al. 2012).
Finally, it is possible that the association 
between serum PFOA and kidney function 
reflects causal effects in both directions (i.e., 
decreased kidney function causes increased 
PFOA in serum and increased serum PFOA 
causes decreased kidney function), potentially 
depending on the magnitude of exposure or 
characteristics of the exposed population.
Our study has additional limitations. 
First, information on residential history and 
potential confounders was self­reported, inev­
itably leading to some misclassification and 
potentially resulting in residual confounding. 
However, in contrast to the general popula­
tion, exposure to PFOA in this population 
was driven mostly by residential water dis­
trict, and was only weakly correlated with 
markers of socioeconomic status and personal 
behaviors (Steenland et al. 2009a). Second, 
although our exposure model allowed us to 
predict serum PFOA levels at birth or during 
early life, no historical information was avail­
able about potential confounders. However, 
most known potential confounders in this 
population are either time­invariant (e.g., sex, 
race) or likely to vary only slowly over time 
Figure 2. Causal diagram illustrating potential for direct and reverse causation. (A) The causal effect of the 
biologically effective dose of PFOA (PFOA exposure) on kidney function was approximated by relating serum 
levels of PFOA (an imperfect marker of the biologic effective dose) to eGFR (an imperfect marker of kidney 
function), controlling for common causes of PFOA exposure and kidney function, which may confound the 
association. Reverse causation occurs when kidney function alters our marker of exposure, represented 
by the arrow from kidney function to serum PFOA. (B) Biological exposure is determined by environmental 
levels of PFOA, which can also be used to predict serum levels of PFOA. Because kidney function does not 
affect predicted PFOA, analyses using predicted PFOA cannot represent reverse causation.
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(e.g., household income). Third, because the 
number of participants with an eGFR sug­
gestive of kidney disease was small, we were 
unable to make comparisons between those 
with and without kidney disease. Last, given 
the unique nature of exposures in this study 
population, our results may not be generaliz­
able to other populations, those with lower 
exposures, or older individuals. On the other 
hand, our study has a number of strengths, 
including a large population with relatively 
well characterized exposures to high levels of 
PFOA, background levels of other PFAAs, 
and the availability of a prediction model 
of historical exposures that is unlikely to be 
influenced by kidney function.
Conclusions
Although we observed an association between 
measured serum PFOA levels and a marker 
of reduced kidney function in children and 
adolescents, our findings highlight the possibil­
ity that this association and resulting increased 
concentrations of PFOA may, at least in part, 
be a consequence, rather than a cause, of 
decreased kidney function. We were not able 
to predict historical serum concentrations of 
other common PFAAs as we could for PFOA, 
but we hypothesize that the observed cross­
sectional associations of measured serum con­
centrations of PFOS, PFNA, and PFHxS with 
decreased kidney function may also be attribut­
able at least partly to reverse causation. Further 
research in the context of prospective cohort 
studies is needed to clearly establish whether 
the observed associations of eGFR with PFAAs 
may be the cause or result of reduced renal 
function, or a combination of both.
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